These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 21515926

  • 1. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
    Shimada K.
    Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
    [Abstract] [Full Text] [Related]

  • 2. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R.
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [Abstract] [Full Text] [Related]

  • 3. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [Abstract] [Full Text] [Related]

  • 4. [Intravascular large B-cell lymphoma: an important cause of fever of unknown origin].
    Masaki Y, Miki M, Sakai T, Sawaki T, Fukushima T, Umehara H.
    Brain Nerve; 2011 May; 63(5):435-41. PubMed ID: 21515922
    [Abstract] [Full Text] [Related]

  • 5. Central nervous system involvement in diffuse large B-cell lymphoma.
    Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y.
    Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
    [Abstract] [Full Text] [Related]

  • 6. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [Abstract] [Full Text] [Related]

  • 7. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
    Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA.
    Cancer; 2012 Jun 01; 118(11):2944-51. PubMed ID: 22006274
    [Abstract] [Full Text] [Related]

  • 8. [Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen].
    Miura Y, Toyooka N, Iwai F, Matsui Y, Hirai M, Kaneko H, Watanabe M, Tsudo M.
    Rinsho Ketsueki; 2011 Dec 01; 52(12):1876-81. PubMed ID: 22241155
    [Abstract] [Full Text] [Related]

  • 9. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.
    Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K.
    Cancer Sci; 2012 Feb 01; 103(2):245-51. PubMed ID: 22044593
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
    Ghose A, Kundu R, Latif T.
    Crit Rev Oncol Hematol; 2014 Sep 01; 91(3):292-303. PubMed ID: 24698003
    [Abstract] [Full Text] [Related]

  • 11. [Case of peritubular capillary dominant intravascular large B-cell lymphoma (PTC dominant IVLBCL) successfully treated with chemotherapy].
    Kado H, Hatta T, Ueno R, Takagi A, Segawa H, Sawada K, Hosokawa Y.
    Nihon Jinzo Gakkai Shi; 2011 Sep 01; 53(7):1046-52. PubMed ID: 22073871
    [Abstract] [Full Text] [Related]

  • 12. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
    Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group.
    Cancer; 2006 Jun 15; 106(12):2540-6. PubMed ID: 16700036
    [Abstract] [Full Text] [Related]

  • 13. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP.
    Cancer; 2010 Sep 15; 116(18):4283-90. PubMed ID: 20564149
    [Abstract] [Full Text] [Related]

  • 14. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C.
    Ann Hematol; 2011 May 15; 90(5):539-46. PubMed ID: 20960190
    [Abstract] [Full Text] [Related]

  • 15. [Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen].
    Nakazato T, Suzuki K, Mihara A, Sanada Y, Yoshida S, Kakimoto T.
    Rinsho Ketsueki; 2010 Feb 15; 51(2):148-52. PubMed ID: 20379108
    [Abstract] [Full Text] [Related]

  • 16. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?
    Siegal T, Goldschmidt N.
    Blood Rev; 2012 May 15; 26(3):97-106. PubMed ID: 22244544
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T, Tóth E, Molnár Z, Várady E, Deák B, Horváth A, Horváth GI, Eid H, Schneider K, Lovey J, Keresztes S, Esik O, Lengyel Z, Rosta A.
    Orv Hetil; 2004 Dec 12; 145(50):2531-7. PubMed ID: 15662753
    [Abstract] [Full Text] [Related]

  • 18. Intravascular large B-cell lymphoma of the skin: typical clinical manifestations and a favourable response to rituximab-containing therapy.
    Feldmann R, Schierl M, Sittenthaler M, Jahn R, Wogritsch C, Cerroni L, Steiner A, Breier F.
    Dermatology; 2009 Dec 12; 219(4):344-6. PubMed ID: 19590171
    [Abstract] [Full Text] [Related]

  • 19. Improving outcomes for patients with diffuse large B-cell lymphoma.
    Flowers CR, Sinha R, Vose JM.
    CA Cancer J Clin; 2010 Dec 12; 60(6):393-408. PubMed ID: 21030533
    [Abstract] [Full Text] [Related]

  • 20. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
    Fukuhara S, Watanabe T, Munakata W, Mori M, Maruyama D, Kim SW, Kobayashi Y, Taniguchi H, Maeshima AM, Tanosaki R, Matsuno Y, Tobinai K.
    Eur J Haematol; 2011 Nov 12; 87(5):434-40. PubMed ID: 21740461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.